Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed

References

• El-Zanaty F, Way A. Egypt Demographic and Health Survey 2008. Cairo, Egypt: Ministry of Health, El-Zanaty and Associates, and Macro International; 2009:431.
   Google Scholar
• Waked I, Doss W, El-Sayed MH, et al. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol. 2014;15(2):45–52. doi:10.1016/j.ajg.2014.04.00325097045
   PubMed Web of Science ®Google Scholar
• Planas R, Ballesté B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol. 2004;40(5):823–830. doi:10.1016/j.jhep.2004.01.00515094231
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.2010721296855
   PubMed Web of Science ®Google Scholar
• Ryerson AB, Eheman CR, Altekruse SF, et al. Annual report to the Nation on the Status of Cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312–1337. doi:10.1002/cncr.2993626959385
   PubMed Web of Science ®Google Scholar
• Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4(9):1065. doi:10.1038/20539734402
   PubMed Web of Science ®Google Scholar
• Burra P, Giannini EG, Caraceni P, et al. Specific issues concerning the management of patients on the waiting list and after liver transplantation. Liver Int. 2018;38(8):1338–1362. doi:10.1111/liv.1375529637743
   PubMed Web of Science ®Google Scholar
• Buonfiglioli F, Brillanti S. Direct antiviral therapy for hepatitis C and hepatocellular carcinoma: facing the conundrum. Hepatoma Res. 2018;4:6. doi:10.20517/2394-5079.2017.42
   Google Scholar
• Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43(6):1303–1310. doi:10.1002/hep.2117616729298
   PubMed Web of Science ®Google Scholar
• Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719–726.27084592
   PubMed Web of Science ®Google Scholar
• Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166(9):637–648. doi:10.7326/M16-257528319996
   PubMed Web of Science ®Google Scholar
• Zanetto A, Shalaby S, Ferrarese A, et al. Direct-acting antivirals and hepatocellular carcinoma occurrence and recurrence in hepatitis C virus-related liver cirrhosis: fact or fiction. Hepatoma Res. 2018;4:70. doi:10.20517/2394-5079.2018.102
   Google Scholar
• Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77–87. doi:10.1002/hep.2725925069599
   PubMed Web of Science ®Google Scholar
• Gayam V, Khalid M, Mandal AK, et al. Direct-acting antivirals in chronic hepatitis C genotype 4 infection in community care setting. Gastroenterol Res. 2018;11(2):130. doi:10.14740/gr999w
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153(4):996–1005. doi:10.1053/j.gastro.2017.06.01228642197
   PubMed Web of Science ®Google Scholar
• Li DK, Ren Y, Fierer DS, et al. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study. Hepatology. 2018;67(6):2244–2253. doi:10.1002/hep.2970729205416
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017;pii: S0168–8278 (17)32273–0.
   Google Scholar
• Rinaldi L, Di Francia R, Coppola N, et al. Hepatocellular carcinoma in HCV cirrhosis after viral clearance with direct acting antiviral therapy: preliminary evidence and possible meanings. WCRJ. 2016;3:e748.
   Google Scholar
• Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals. J Hepatol. 2016;65:727–733. doi:10.1016/j.jhep.2016.06.01527349488
   PubMed Web of Science ®Google Scholar
• Kozbial K, Moser S, Schwarzer R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol. 2016;65(4):856–858. doi:10.1016/j.jhep.2016.06.00927318327
   PubMed Web of Science ®Google Scholar
• Calvaruso V, Cabibbo G, Cacciola I, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology. 2018;155(2):411–421. doi:10.1053/j.gastro.2018.04.00829655836
   PubMed Web of Science ®Google Scholar
• Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493–1505. doi:10.1002/hep.2844626754432
   PubMed Web of Science ®Google Scholar
• Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133:592–599. doi:10.7326/0003-4819-133-8-200010170-0000911033586
   PubMed Web of Science ®Google Scholar
• Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology. 2003;38:50–56. doi:10.1053/jhep.2003.5029112829986
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Fallahi P, et al. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care. 2005;28(10):2548–2550. doi:10.2337/diacare.28.10.254816186298
   PubMed Web of Science ®Google Scholar
• Berge E, Arencibia A, Otón E, Cejas L, Acosta S, Pérez F. Clinical outcomes of direct-acting antiviral therapy in patients with compensated hepatitis C virus-related cirrhosis. Hepatoma Res. 2017;3(9):209–214. doi:10.20517/2394-5079.2017.28
   Google Scholar
• Romano A, Angeli P, Piovesan S, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. J Hepatol. 2018;69(2):345–352. doi:10.1016/j.jhep.2018.03.00929551707
   PubMed Web of Science ®Google Scholar